NR 546 ADVANCED PHARMACOLOGY 2026/2027 TEST
BANK WITH SOLUTIONS | 300 ACTUAL EXAM
QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ |
CHAMBERLAIN UNIVERSITY (BRAND NEW!!)
CORE DOMAINS
1. Functional Neuroanatomy and Ethics
2. Neurotransmission and Pharmacokinetics
3. Antipsychotic Medications and Metabolic Monitoring
4. Antidepressants and Mood Stabilizers
5. Anxiolytics and Hypnotics
6. Psychostimulants and ADHD Management
7. Substance Use Disorder Pharmacotherapy
8. CYP450 Drug Interactions and Pharmacogenomics
9. Special Populations and Off-Label Prescribing
10.Legal and Ethical Issues in Psychopharmacology
INTRODUCTION
This comprehensive test bank is designed to prepare PMHNP students for the NR
546 Advanced Pharmacology midterm and final examinations. The questions
cover foundational neuroanatomy, neurotransmitter systems, pharmacokinetics,
pharmacodynamics, and clinical applications of psychotropic medications. Each
question includes the correct answer with a detailed rationale to strengthen
clinical reasoning and exam mastery. The content is organized to facilitate
systematic review across all major exam domains, including CYP450 drug
,interactions, receptor pharmacology, brain pathways, and medication
management for psychiatric disorders. Updated for the 2026/2027 academic
cycle, this resource aligns with national APRN pharmacology standards.
SECTION ONE: QUESTIONS 1–300
1. A psychiatric medication undergoes extensive first-pass metabolism. The
clinical consequence is that:
A. The drug bypasses the liver entirely when taken orally
B. Only a fraction of the oral dose reaches systemic circulation, often
requiring higher oral than parenteral doses
C. All of the dose reaches the bloodstream unchanged after oral
administration
D. The drug must always be given rectally to work
Correct answer B.
RATIONALE: Portal circulation delivers oral drugs directly to hepatic
enzymes, so first-pass metabolism degrades a portion before it reaches the
blood, raising oral dose requirements. The drug does not bypass the liver
orally, full bioavailability is false, and rectal dosing is not a general rule.
2. A client takes a new antidepressant with a half-life of 30 hours.
Approximately how long until steady-state plasma levels are reached?
A. About 5 to 7 days, since steady state requires roughly five half-lives
B. About 60 hours, since two half-lives suffice
C. About 30 minutes after the first dose
D. About 3 months regardless of half-life
Correct answer A.
RATIONALE: Steady state is achieved after approximately five half-lives,
so five times 30 hours equals 150 hours, about six days. Two half-lives,
minutes, and months all misapply the steady-state rule.
3. A client who smokes two packs daily takes a medication metabolized by
CYP1A2. After smoking cessation, the nurse anticipates that:
A. Plasma levels will rise as the loss of CYP1A2 induction slows metabolism,
, requiring dose reduction
B. Plasma levels will fall because smoking protects the drug
C. No change in levels occurs since smoking affects only the lungs
D. The drug must be switched to a parenteral form immediately
Correct answer A.
RATIONALE: Polycyclic aromatic hydrocarbons in smoke induce CYP1A2;
cessation removes the induction, slowing clearance and raising levels of
drugs such as olanzapine, clozapine, and theophylline. Smoking does not
lower or ignore drug levels, and the route is irrelevant.
4. A client with CYP2D6 poor metabolizer genotype takes nortriptyline and
develops marked side effects at a standard dose. The best explanation is:
A. The client has developed a sudden allergy to the medication
B. Poor metabolizers clear drugs faster than extensive metabolizers
C. Genotype has no influence on medication response
D. Reduced enzyme activity slows clearance, so the drug and its
metabolites accumulate
Correct answer D.
RATIONALE: CYP2D6 poor metabolizers have reduced enzyme activity,
leading to slower clearance and accumulation of drugs like nortriptyline,
increasing the risk of side effects. This is not an allergy, and poor
metabolizers do not clear drugs faster.
5. Which brain region is primarily responsible for executive function, decision-
making, and is implicated in the negative symptoms of schizophrenia when
hypofunctional?
A. Amygdala
B. Prefrontal cortex
C. Hippocampus
D. Basal ganglia
Correct answer B.
RATIONALE: The prefrontal cortex is primarily responsible for executive
function, decision-making, impulse control, and social behavior.
Hypofunction of the prefrontal cortex (hypofrontality) is associated with
, negative symptoms of schizophrenia. The amygdala is involved in fear and
anxiety. The hippocampus is involved in memory formation. The basal
ganglia are involved in motor control.
6. A patient presents with difficulty understanding spoken language and
producing fluent speech. Which area of the brain is most likely affected?
A. Broca's area
B. Wernicke's area
C. Prefrontal cortex
D. Occipital lobe
Correct answer B.
RATIONALE: Wernicke's area, located in the temporal lobe, is
responsible for speech comprehension. Damage results in receptive
aphasia. Broca's area is responsible for speech production; damage results
in expressive aphasia. The prefrontal cortex is responsible for executive
function. The occipital lobe is responsible for visual processing.
7. Which brain structure is associated with both memory and anxiety?
A. Amygdala
B. Hippocampus
C. Thalamus
D. Cerebellum
Correct answer B.
RATIONALE: The hippocampus is involved in memory formation and is
also implicated in anxiety disorders. The amygdala is primarily associated
with fear and anxiety but is not primarily involved in memory. The thalamus
is a sensory relay station. The cerebellum coordinates voluntary
movements.
8. A patient with damage to the dorsolateral prefrontal cortex would most
likely exhibit which of the following?
A. Impaired speech comprehension
B. Difficulty with planning and problem-solving
C. Visual hallucinations
D. Loss of coordination
BANK WITH SOLUTIONS | 300 ACTUAL EXAM
QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ |
CHAMBERLAIN UNIVERSITY (BRAND NEW!!)
CORE DOMAINS
1. Functional Neuroanatomy and Ethics
2. Neurotransmission and Pharmacokinetics
3. Antipsychotic Medications and Metabolic Monitoring
4. Antidepressants and Mood Stabilizers
5. Anxiolytics and Hypnotics
6. Psychostimulants and ADHD Management
7. Substance Use Disorder Pharmacotherapy
8. CYP450 Drug Interactions and Pharmacogenomics
9. Special Populations and Off-Label Prescribing
10.Legal and Ethical Issues in Psychopharmacology
INTRODUCTION
This comprehensive test bank is designed to prepare PMHNP students for the NR
546 Advanced Pharmacology midterm and final examinations. The questions
cover foundational neuroanatomy, neurotransmitter systems, pharmacokinetics,
pharmacodynamics, and clinical applications of psychotropic medications. Each
question includes the correct answer with a detailed rationale to strengthen
clinical reasoning and exam mastery. The content is organized to facilitate
systematic review across all major exam domains, including CYP450 drug
,interactions, receptor pharmacology, brain pathways, and medication
management for psychiatric disorders. Updated for the 2026/2027 academic
cycle, this resource aligns with national APRN pharmacology standards.
SECTION ONE: QUESTIONS 1–300
1. A psychiatric medication undergoes extensive first-pass metabolism. The
clinical consequence is that:
A. The drug bypasses the liver entirely when taken orally
B. Only a fraction of the oral dose reaches systemic circulation, often
requiring higher oral than parenteral doses
C. All of the dose reaches the bloodstream unchanged after oral
administration
D. The drug must always be given rectally to work
Correct answer B.
RATIONALE: Portal circulation delivers oral drugs directly to hepatic
enzymes, so first-pass metabolism degrades a portion before it reaches the
blood, raising oral dose requirements. The drug does not bypass the liver
orally, full bioavailability is false, and rectal dosing is not a general rule.
2. A client takes a new antidepressant with a half-life of 30 hours.
Approximately how long until steady-state plasma levels are reached?
A. About 5 to 7 days, since steady state requires roughly five half-lives
B. About 60 hours, since two half-lives suffice
C. About 30 minutes after the first dose
D. About 3 months regardless of half-life
Correct answer A.
RATIONALE: Steady state is achieved after approximately five half-lives,
so five times 30 hours equals 150 hours, about six days. Two half-lives,
minutes, and months all misapply the steady-state rule.
3. A client who smokes two packs daily takes a medication metabolized by
CYP1A2. After smoking cessation, the nurse anticipates that:
A. Plasma levels will rise as the loss of CYP1A2 induction slows metabolism,
, requiring dose reduction
B. Plasma levels will fall because smoking protects the drug
C. No change in levels occurs since smoking affects only the lungs
D. The drug must be switched to a parenteral form immediately
Correct answer A.
RATIONALE: Polycyclic aromatic hydrocarbons in smoke induce CYP1A2;
cessation removes the induction, slowing clearance and raising levels of
drugs such as olanzapine, clozapine, and theophylline. Smoking does not
lower or ignore drug levels, and the route is irrelevant.
4. A client with CYP2D6 poor metabolizer genotype takes nortriptyline and
develops marked side effects at a standard dose. The best explanation is:
A. The client has developed a sudden allergy to the medication
B. Poor metabolizers clear drugs faster than extensive metabolizers
C. Genotype has no influence on medication response
D. Reduced enzyme activity slows clearance, so the drug and its
metabolites accumulate
Correct answer D.
RATIONALE: CYP2D6 poor metabolizers have reduced enzyme activity,
leading to slower clearance and accumulation of drugs like nortriptyline,
increasing the risk of side effects. This is not an allergy, and poor
metabolizers do not clear drugs faster.
5. Which brain region is primarily responsible for executive function, decision-
making, and is implicated in the negative symptoms of schizophrenia when
hypofunctional?
A. Amygdala
B. Prefrontal cortex
C. Hippocampus
D. Basal ganglia
Correct answer B.
RATIONALE: The prefrontal cortex is primarily responsible for executive
function, decision-making, impulse control, and social behavior.
Hypofunction of the prefrontal cortex (hypofrontality) is associated with
, negative symptoms of schizophrenia. The amygdala is involved in fear and
anxiety. The hippocampus is involved in memory formation. The basal
ganglia are involved in motor control.
6. A patient presents with difficulty understanding spoken language and
producing fluent speech. Which area of the brain is most likely affected?
A. Broca's area
B. Wernicke's area
C. Prefrontal cortex
D. Occipital lobe
Correct answer B.
RATIONALE: Wernicke's area, located in the temporal lobe, is
responsible for speech comprehension. Damage results in receptive
aphasia. Broca's area is responsible for speech production; damage results
in expressive aphasia. The prefrontal cortex is responsible for executive
function. The occipital lobe is responsible for visual processing.
7. Which brain structure is associated with both memory and anxiety?
A. Amygdala
B. Hippocampus
C. Thalamus
D. Cerebellum
Correct answer B.
RATIONALE: The hippocampus is involved in memory formation and is
also implicated in anxiety disorders. The amygdala is primarily associated
with fear and anxiety but is not primarily involved in memory. The thalamus
is a sensory relay station. The cerebellum coordinates voluntary
movements.
8. A patient with damage to the dorsolateral prefrontal cortex would most
likely exhibit which of the following?
A. Impaired speech comprehension
B. Difficulty with planning and problem-solving
C. Visual hallucinations
D. Loss of coordination
